Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Low J&J Vaccine Demand Forces Production Halt At S.Africa’s Aspen Unit – $JNJ $DIA

By John F. Heerdink, Jr.

Reportedly, South Africa’s Aspen Pharmacare will stop making COVID-19 vaccines from the end of this month due to a lack of orders. Aspen currently produces vaccines for Johnson & Johnson.

In March, it struck a deal to produce, price, and sell its own-brand version of the shot for African markets. That deal was considered a game-changer for a continent with low vaccine rates. According to the African Centres for Disease Control and Prevention, only a fifth of adults in Africa are fully vaccinated, and demand for shots has failed to materialize.

“The thing here is that we don’t know if we will get further orders from J&J. But we are finishing off production of what we’ve got,” stated Stavros Nicolaou, group senior executive at Aspen.

Aspen has had no orders for its Aspenovax vaccine and has not received orders from Johnson & Johnson beyond August. Without new orders, Aspen would have to shut down all of its 450 million-dose annual production capacity, as per reports.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: S.Africa's Aspen to halt COVID vaccine output as J&J orders dry up in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us